Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib

The phase 3 Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation (ADMIRAL) trial demonstrated the superiority of the FLT3 inhibitor, gilteritinib, to salvage chemotherapy (SC) in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Catherine C., Levis, Mark J., Perl, Alexander E., Hill, Jason E., Rosales, Matt, Bahceci, Erkut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006281/
https://www.ncbi.nlm.nih.gov/pubmed/35130342
http://dx.doi.org/10.1182/bloodadvances.2021006489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006281/
https://www.ncbi.nlm.nih.gov/pubmed/35130342
http://dx.doi.org/10.1182/bloodadvances.2021006489

Ejemplares similares